RenovoRx Profit Margin

The latest profit margin for RNXT is -8.24% as of March 2026. That compares with -42.33% in the prior-year period — up 80.5% year over year. That is below the sector sector average of 19.69%. Investors often review this figure alongside RenovoRx's historical trend and sector peers before judging valuation or financial health.

Over the past year, RNXT's profit margin moved from -42.33% to -8.24% — a 80.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in RenovoRx's valuation or profitability profile.

Against its sector companies, RNXT currently prints -8.24% for profit margin, while the sector average sits near 19.69%. That is roughly 4284.4% below the sector mean. Large gaps often invite a closer look at RenovoRx's growth, margins, and balance sheet.

Profit Margin shows how effectively RenovoRx converts resources into returns. At -8.24%, RNXT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -42.33% in the prior-year period — up 80.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RNXT's profit margin (-8.24%), review year-over-year change from -42.33%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.